Clinical Trial Update: Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, pharmacokinetics, immunogenicity, and pharmacodynamics/efficacy of EDI200 in male infants with X-Linked Hypohidrotic Ectodermal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Hypohidrotic Ectodermal Dysplasia

Drugs mentioned

• EDI200

Snippet

Sponsor: Edimer Pharmaceuticals | Conditions: X-Linked Hypohidrotic Ectodermal Dysplasia | Phase 2 | Status: COMPLETED